CPR Davide Campari-Milano N.V.
Davide Campari-Milano N.V., together with its subsidiaries, trades in alcoholic and non-alcoholic beverages in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. It offers a range of products, including aperitifs, vodka, whisky, rum, agave, cognac, and champagne under the Aperol, Campari, Picon, Cynar, Sarti Rosa, Campari Soda, Crodino, Aperol Spritz RTE, Wild Turkey, Appleton Estate, Wray and Nephew, The GlenGrant, Wilderness Trail, Espolòn, Ancho Reyes, Montelobos, Grand Marnier, Courvoisier, Bisquit, Champagne Lallier, SKYY Vodka, Bulldog Gin, Averna, Braulio, Forty Creek, Frangelico, Cabo Wabo, Del Professore, Mondoro, Riccadonna, La Mauny, Trois Rivieres, Kingston 62, O'ndina, Bickens, Dreher, Ouzo 12, Sagabita, and Zedda Piras brand names. Davide Campari-Milano N.V. was founded in 1860 and is headquartered in Sesto San Giovanni, Italy. Davide Campari-Milano N.V. operates as a subsidiary of Lagfin S.C.A.…
Industry Peers
Beverages - Wineries & DistilleriesKey Statistics
About Davide Campari-Milano (BIT: CPR)
›
Davide Campari-Milano (BIT: CPR) is listed on Borsa Italiana, where its shares trade in EUR. It belongs to the Beverages - Wineries & Distilleries industry, part of the Consumer Defensive sector, and reports about 4,935 employees.
The shares were at 6.494 EUR on 19 November 2026, up 14.9% over 52 weeks. Its 52-week range is 5.274 EUR to 6.910 EUR: the price is 6.0% below the high and 23.1% above the low.
At a market capitalisation of 7.79B EUR, it trades at 40.6 times trailing earnings and 18.4 times forward earnings. The median trailing P/E of its 17 largest Beverages - Wineries & Distilleries peers is 20.5, a premium of 98% for CPR. It pays a dividend yielding 1.49% (it pays out 65% of its earnings), against a median of 3.21% among the dividend payers in that peer group.
Davide Campari-Milano reports return on equity of 9.0%, an operating margin of 18.1% and revenue down 1.0% year over year.
Its debt exceeds its cash by 2.10B EUR, a debt-to-equity ratio of 0.66. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 21 analysts cover the stock, with an average rating of Buy; their mean price target of 7.186 EUR is 10.7% above the current price. The next earnings report is expected on 3 March 2027.